logo
Hydration Is Safety: Protecting Youth Athletes from Dehydration & Heat Illness

Hydration Is Safety: Protecting Youth Athletes from Dehydration & Heat Illness

Even at the collegiate level - where medical support is more comprehensive - the risks remain high -
'NSA recommends a hydration guideline popularized by NFL legend Tom Brady, now widely adopted across youth sports programs'— Jason Gruner
NAPLES, FL, UNITED STATES, July 20, 2025 / EINPresswire.com / -- Naples Soccer Academy (NSA), a club-neutral 501(c)(3) nonprofit dedicated exclusively to advancing female youth soccer training and development in Southwest Florida (EIN-99-2663889), is issuing an public service announcement on a critical issue impacting youth athletes: dehydration.
Recent studies have highlighted a preventable trend - thousands of young athletes across the country begin practices and games in a dehydrated state, often resulting in heat-related illnesses and emergency hospital visits. Despite casual mentions during pre-season meetings, hydration is too often overlooked as a core component of athlete safety.
According to a 2022 systematic review published in Nutrients, an alarming 81% of youth athletes were found to be hypohydrated, meaning their bodies were already dehydrated before exercise began. This level of dehydration can significantly impair: - Physical performance- Cognitive function- Thermoregulation.
Even at the collegiate level - where medical support is more comprehensive - the risks remain high. A separate study published in Current Sports Medicine Reports revealed: - 8% of exertional heat illness (EHI) cases required emergency hospitalization - Common incidents included heat cramps, syncope (fainting), and heat stroke.
'Hydration is not just about performance - it's about safety,' said Jason Gruner, Executive Director of Naples Soccer Academy. 'Every parent, coach, and athlete should treat proper hydration as seriously as any piece of protective equipment.'
To help simplify the message, NSA recommends a hydration guideline popularized by NFL legend Tom Brady, now widely adopted across youth sports programs: Drink at least half your body weight in ounces of water per day. For optimum safety during hot weather or intense training, aim for your full body weight in ounces, supplemented with electrolytes that are free from sugar and caffeine.
Examples:
120 lb. athlete -> 60/120 oz of water daily-
160 lb. athlete -> 80/160 oz of water daily-
NSA emphasizes that no athlete should ever be denied water when requested – in alignment with SafeSport policies and recommendations. Heat illness and dehydration are entirely preventable when hydration is prioritized.
About Naples Soccer Academy (NSA): Naples Soccer Academy is a club-neutral, 501(c)(3) nonprofit (EIN-99-2663889) committed to empowering young female athletes through elite-level training and mentorship. Led by collegiate and professional female athletes, NSA offers year-round development in a supportive, athlete-first environment designed to elevate performance on and off the pitch
Jason T. Gruner
Naples Soccer Academy Corporation
+1 239-272-1082
email us here
Visit us on social media:
Instagram
Facebook
TikTok
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wisconsin football offers five-star recruit in the class of 2027
Wisconsin football offers five-star recruit in the class of 2027

Yahoo

time15 minutes ago

  • Yahoo

Wisconsin football offers five-star recruit in the class of 2027

Wisconsin football is setting its sights high in the 2027 recruiting cycle, especially at the tight end position. After offering four-star TE Jaxon Dollar on Tuesday, the program also extended an offer to five-star TE Ahmad Hudson -- one of the nation's top players in the class. 247Sports specifically ranks Hudson as the No. 10 overall player in the 2027 cycle, the No. 1 tight end and the No. 1 player from his home state of Louisiana. Wisconsin is unsurprisingly not alone on the five-star recruit's offer sheet. As of July 23, other programs in pursuit of Hudson include Alabama, Florida State, LSU, Texas A&M, Auburn, Florida, Miami, Nebraska, North Carolina, Ohio State, Ole Miss, Oregon, Texas and USC. 247Sports currently lists Alabama, Baylor, Florida State, in-state LSU and Texas A&M as the early favorites in his recruitment, while On3/Rivals gives LSU (95.9%) a prohibitive early advantage over Nebraska (2%) and others. The 6-foot-6 tight end prospect is also a four-star power forward recruit on the basketball court. Only LSU, Grambling State and Louisiana Tech are listed on his basketball offer sheet. Wisconsin will have significant competition for Hudson's commitment. The program has not landed a five-star recruit since offensive tackle Nolan Rucci during the 2021 cycle. It only has five five-star signees in the online recruiting rankings era: 2001 DT Anttaj Hawthorne, 2003 DE Justin Ostrowski, 2007 OT Josh Oglesby, 2019 OT Logan Brown and Rucci. As noted in our story on Wisconsin's offer to Dollar, another blue-chip tight end in the class, the program is looking to rebuild its tight end room as it transitions back to a pro-style system on offense. Top talent at the position will be paramount to the scheme's success. That reality differs from Phil Longo's air raid scheme, which put more emphasis on speed and talent at wide receiver. Contact/Follow on X (formerly Twitter) and like our page on to follow ongoing coverage of Wisconsin Badgers news, notes and opinion This article originally appeared on Badgers Wire: Wisconsin football recruiting offer 2027 five-star Ahmad Hudson

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

Yahoo

time15 minutes ago

  • Yahoo

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio

U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates
U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates

Yahoo

time15 minutes ago

  • Yahoo

U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates

HOUSTON, July 23, 2025--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the three months and six months ended June 30, 2025, on Wednesday, August 6, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, August 7, 2025. Conference Call Date: Thursday, August 7, 2025 Time: 10:30 am Eastern / 9:30 am Central Dial-In Number: (800) 343-4136 Primary or (203) 518-9843 Alternate Conference ID: USPHQ225 (In order to join this conference call,you will be required to provide the Conference ID listed above) To participate, please call in 15 minutes prior to start time. To listen to the live call, please go to and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until November 5, 2025 at USPH's website. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 768 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release. View source version on Contacts U.S. Physical Therapy, Hendrickson, Chief Financial OfficerEmail: Chendrickson@ Chris Reading, Chief Executive Officer(713) 297-7000 Three Part AdvisorsJoe Noyons(817) 778-8424

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store